Cost effectiveness of vildagliptin versus glimepiride as add-on treatment to metformin for the treatment of diabetes mellitus type 2 patients in Greece

被引：0
|
作者：
Hara Kousoulakou
Magdalini Hatzikou
Varvara Baroutsou
John Yfantopoulos
机构：
[1] University of Peloponnese,
[2] Novartis Hellas SACI,undefined
[3] National and Kapodistrian University of Athens,undefined
[4] School of Economics and Political Science ,undefined
来源：
Cost Effectiveness and Resource Allocation | / 15卷
关键词：
Vildagliptin; Type 2 diabetes mellitus; Cost-effectiveness; Greece;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [31] Oral add-on therapy to metformin in type 2 diabetes mellitus: A direct comparison beween canagliflozin and glimepiride
    Seufert, J.
    DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT, 2014, 139 : S65 - S69
  • [32] Comparison between the Therapeutic Effect of Metformin, Glimepiride and Their Combination as an Add-On Treatment to Insulin Glargine in Uncontrolled Patients with Type 2 Diabetes
    Park, Cheol-Young
    Kang, Jun Goo
    Chon, Suk
    Noh, Junghyun
    Oh, Seung Joon
    Lee, Chang Beom
    Park, Sung Woo
    PLOS ONE, 2014, 9 (03):
  • [33] Cost-effectiveness of dapagliflozin versus DPP-4 inhibitors as an add-on to Metformin in the Treatment of Type 2 Diabetes Mellitus from a UK Healthcare System Perspective
    M. Charokopou
    P. McEwan
    S. Lister
    L. Callan
    K. Bergenheim
    K. Tolley
    R. Postema
    R. Townsend
    M. Roudaut
    BMC Health Services Research, 15
  • [34] Cost-effectiveness of dapagliflozin versus DPP-4 inhibitors as an add-on to Metformin in the Treatment of Type 2 Diabetes Mellitus from a UK Healthcare System Perspective
    Charokopou, M.
    McEwan, P.
    Lister, S.
    Callan, L.
    Bergenheim, K.
    Tolley, K.
    Postema, R.
    Townsend, R.
    Roudaut, M.
    BMC HEALTH SERVICES RESEARCH, 2015, 15
  • [35] Dapagliflozin plus Saxagliptin Add-On vs. Glimepiride Add-On to Metformin in Patients with Poorly Controlled Type 2 Diabetes
    Frias, Juan P.
    Gonzalez-Galvez, Guillermo
    Johnsson, Eva K.
    Maaske, Jill
    Peters, Anne
    DIABETES, 2018, 67
  • [36] Cost-Utility Analysis of Dapagliflozin Versus Saxagliptin Treatment as Monotherapy or Combination Therapy as Add-on to Metformin for Treating Type 2 Diabetes Mellitus
    Hu, Shanshan
    Deng, Xun
    Ma, Yanjiao
    Li, Zhilei
    Wang, Yuhang
    Wang, Yong
    APPLIED HEALTH ECONOMICS AND HEALTH POLICY, 2021, 19 (01) : 69 - 79
  • [37] Cost-Utility Analysis of Dapagliflozin Versus Saxagliptin Treatment as Monotherapy or Combination Therapy as Add-on to Metformin for Treating Type 2 Diabetes Mellitus
    Shanshan Hu
    Xun Deng
    Yanjiao Ma
    Zhilei Li
    Yuhang Wang
    Yong Wang
    Applied Health Economics and Health Policy, 2021, 19 : 69 - 79
  • [38] Efficacy and tolerability of vildagliptin as an add-on to nateglinide in Japanese patients with type 2 diabetes mellitus
    Fujimaki, K.
    Hirose, T.
    Someya, Y.
    Yoshihara, T.
    Fujitani, Y.
    Watada, H.
    DIABETOLOGIA, 2012, 55 : S357 - S357
  • [39] ESTIMATING THE COST EFFECTIVENESS IN THE UK OF VILDAGLIPTIN COMPARED TO PIOGLITAZONE AS ADD-ON THERAPY TO METFORMIN USING THE SHEFFIELD TYPE 2 DIABETES MODEL
    Brennan, A.
    Gillett, M.
    Duenas, A.
    VALUE IN HEALTH, 2008, 11 (06) : A501 - A501
  • [40] Vildagliptin add-on to metformin versus metformin uptitration in Chinese patients with type 2 diabetes: A sub-group analysis of the VISION study
    Ji, Linong
    Pan, Changyu
    Lu, Juming
    Zhu, Dalong
    Li, Hong
    Li, Qiang
    Li, Qifu
    Peng, Yongde
    Tian, Haoming
    Yao, Chen
    Zhao, Zhigang
    Wang, Binhui
    Cai, Qin
    DIABETES-METABOLISM RESEARCH AND REVIEWS, 2015, 31 : 1 - 1
12345